Advanced search
Publication Cover
Future Oncology Volume 17, 2021 - Issue 10
Submit an article Journal homepage
5,337
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Patient-Reported Outcomes with Durvalumab by PD-L1 Expression and Prior Chemoradiotherapy-Related Variables in Unresectable Stage III Non-Small-Cell Lung Cancer

Marina C Garassino1 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3821-5598View further author information
ORCID Icon,
Luis Paz-Ares2 Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense & CNIO, Madrid, 28041, SpainView further author information
,
Rina Hui3 Westmead Hospital & the University of Sydney, Sydney, NSW, 2145, AustraliaView further author information
,
Corinne Faivre-Finn4 The University of Manchester & The Christie NHS Foundation Trust, Manchester, M20 4BX, UKView further author information
,
Alex Spira5 Virginia Cancer Specialists Research Institute, Fairfax, VA, & US Oncology Research, The Woodlands, TX22031, USAView further author information
,
David Planchard6 Institut Gustave Roussy, Department of Medical Oncology, Thoracic Group, Villejuif, 94805, FranceView further author information
,
Mustafa Özgüroğlu7 Istanbul University – Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, 34320, TurkeyView further author information
,
Davey Daniel8 Sarah Cannon Research Institute/Tennessee Oncology, Chattanooga, TN37203, USAView further author information
,
David Vicente9 Hospital Universitario Virgen Macarena, Seville, 41009, SpainView further author information
,
Shuji Murakami10 Kanagawa Cancer Center, Yokohama, 241-8515, JapanView further author information
,
Corey Langer11 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA19104, USAView further author information
,
Suresh Senan12 Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, 1081, The NetherlandsView further author information
,
David Spigel13 Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN3720231, USAView further author information
,
Anna Rydén14 AstraZeneca, Gothenburg, 431 50, SwedenView further author information
,
Yiduo Zhang15 AstraZeneca, Gaithersburg, MD20878, USAView further author information
,
Cathy O'Brien16 AstraZeneca, Cambridge, CB4 0WG, UKView further author information
,
Phillip A Dennis15 AstraZeneca, Gaithersburg, MD20878, USAView further author information
&
Scott J Antonia17 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL33612, USAView further author information
 show all
Pages 1165-1184 | Received 29 Oct 2020, Accepted 20 Nov 2020, Published online: 15 Feb 2021
Supplemental material

Compliance with EORTC QLQ-C30 and EORTC QLQ-LC13 from baseline to week 48across all PD-L1 subgroups

Download MS Word (90.3 KB)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.